Accordingly, we designed the ASTEROID trial (A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary. The purpose of this study is to see if 40 mg of rosuvastatin taken daily will reduce . statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound- Derived Coronary Atheroma Burden – ASTEROID. Mar 13, Share via: AddThis.

Author: Dakazahn Dagore
Country: Nicaragua
Language: English (Spanish)
Genre: Personal Growth
Published (Last): 1 August 2007
Pages: 323
PDF File Size: 6.93 Mb
ePub File Size: 16.19 Mb
ISBN: 686-8-97130-261-4
Downloads: 30411
Price: Free* [*Free Regsitration Required]
Uploader: Shahn

Figure 2 shows a representative cross-section at baseline and follow-up for a patient who exhibited marked regression of disease.

The ASTEROID trial: coronary plaque regression with high-dose statin therapy.

The magnitude and consistency of regression observed in the current trial are noteworthy. Moreover, arteries undergoing mechanical interventions were included, which could have affected atheroma measurements.

Sign in to save your search Sign in to your personal account. Privacy Policy Terms of Use. Prior intravascular ultrasound IVUS trials have demonstrated slowing or halting of atherosclerosis progression with statin therapy but have not shown convincing evidence of regression using percent atheroma volume PAVthe most rigorous IVUS measure of disease progression and regression.

Categorical variables are described using frequencies, while continuous variables are reported as means with SDs and medians with Initial trials used quantitative coronary angiography or carotid ultrasound to determine the progression rates.

Create a personal account to register for email alerts with links to free full-text articles. The bottom 2 panels illustrate the same cross-sections, but with measurements superimposed.

A secondary efficacy variable, change in normalized total atheroma volume for the entire artery, was also prespecified. The most positive IVUS trials to date have demonstrated a slowing or halting of progression of atherosclerosis during statin treatment.

Sign in to customize your interests Sign in to your personal account. Variability of area measurements obtained with different intravascular ultrasound catheter systems: After he received a nonsteroidal anti-inflammatory agent, renal failure developed, the family declined dialysis, and the patient died 5 days later.


Personnel who were unaware of the coding and were therefore blinded to trjal sequence subsequently analyzed both videotapes. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum axteroid levels: Recently, several active control trials have reported that more intensive statin therapy results in a greater reduction in adverse cardiovascular outcomes compared with more moderate treatment.

Effect of simvastatin on coronary atheroma: The 2 examination results were then resequenced using random assignments generated by an outside statistician. Further studies roeuvastatin needed to determine the effect of the observed changes on clinical outcome. Normalized TAV for each patient was calculated as the average atheroma area multiplied by the median number of comparable cross-sections in pullbacks for all patients completing the trial. For the past 2 decades, clinical trials of antiatherosclerotic drug therapies have sought to reduce coronary disease morbidity and mortality, presumably by decreasing the rate of progression of the underlying atherosclerosis.

The ASTEROID trial: coronary plaque regression with high-dose statin therapy.

Role of the Sponsor: In parallel to clinical outcomes trials, imaging studies have examined the effects of antiatherosclerotic therapies on the progression of atherosclerosis. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. Study concept and design: Adverse events were infrequent and similar to other statin trials. The observed increases in HDL-C in the current study suggest that therapies designed to simultaneously lower LDL-C while raising HDL-C have the potential to substantially reduce lesion burden in patients with established disease.

Hospital de Bellvitge, Barcelona E. Analysis and interpretation of data: A secondary efficacy variable, change in normalized total atheroma volume for the entire artery, was also prespecified. Monitoring of the study and maintenance of the trial database was performed by a contract research organization, Omnicare, under contract to the sponsor. This procedure was designed to obtain a series of cross-sectional images at sites identical to the original examination.

J Am Coll Cardiol. N Engl J Med. A similar procedure was performed for each follow-up videotape. Create a free personal account to make a comment, download free article PDFs, sign up for alerts and more. Clinical trials of combination therapies designed to both lower LDL-C and raise HDL-C using novel antiatherosclerotic therapies are currently under way and will report results within the next 18 months.


Atheroma area was reduced from Manual planimetry was used to trace the leading edges of the luminal and external elastic membrane EEM borders. All 3 efficacy parameters showed statistically significant regression. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. Postmortem examination revealed a fracture of the T11 vertebral body with local muscle hemorrhage. A motorized pullback was repeated under conditions identical to the baseline study. The current study supports several conclusions.

Change in total atheroma volume showed rosuvqstatin 6. Between November and Octoberpatients had a baseline IVUS examination and received at least 1 dose of study drug. We hypothesized that high-intensity statin therapy, designed to reach very low levels of LDL-C, particularly if achieved in conjunction with substantial elevation of HDL-C, might result in regression of coronary atherosclerosis.

Nissen, Nicholls, Schoenhagen, Crowe, Tuzcu.

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: The operator astegoid instructed to select a starting point for interrogation as far distally as could be safely reached.

Effects triao the acyl coenzyme A: Despite the higher standard of evidence required, the current study demonstrated regression for all 3 prespecified IVUS end points with a high level of statistical significance Table 3. A year-old man had an elevated creatine kinase level following an episode of lower back pain that occurred after heavy lifting. Rates of elevation of hepatic enzymes were comparable with those reported in other recent trials using maximal statin dosages.

Back to top Article Information.